Dallas, TX -- (SBWIRE) -- 06/25/2015 -- The report "Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Progressive Supranuclear Palsy and special features on late-stage and discontinued projects.

Complete report on Genital Warts (Condylomata Acuminata) with 27 market data tables and 14 figures, spread across 67 pages is available at http://www.rnrmarketresearch.com/genital-warts-condylomata-acuminata-pipeline-review-h1-2015-market-report.html

Companies discussed in this Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2015 report include Agilvax, Inc., Anaconda Pharma, Biogenomics Limited, BioMAS Ltd., Foamix Pharmaceuticals Ltd., G&E Herbal Biotechnology Co., Ltd., Helix BioPharma Corp., LEO Pharma A/S, MediGene AG, NanoViricides, Inc., Novan, Inc. and Tamir Biotechnology, Inc.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are AP-611074, AS-101, AX-03, HerpeCide-I, human papilloma virus [strains 6,11] (bivalent) vaccine, imiquimod, ingenol mebutate, interferon alfa-2b (recombinant), PP-210, ranpirnase, SB-206, sinecatechins and SRT-100.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=392679
(This is a premium report priced at US$2000 for a single user License.)

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

List of Tables
Number of Products under Development for Genital Warts (Condylomata Acuminata), H1 2015 9
Number of Products under Development for Genital Warts (Condylomata Acuminata) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Genital Warts (Condylomata Acuminata) - Pipeline by Agilvax, Inc., H1 2015 16
Genital Warts (Condylomata Acuminata) - Pipeline by Anaconda Pharma, H1 2015 17
Genital Warts (Condylomata Acuminata) - Pipeline by Biogenomics Limited, H1 2015 18
Genital Warts (Condylomata Acuminata) - Pipeline by BioMAS Ltd., H1 2015 19
Genital Warts (Condylomata Acuminata) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 20
Genital Warts (Condylomata Acuminata) - Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2015 21
Genital Warts (Condylomata Acuminata) - Pipeline by Helix BioPharma Corp., H1 2015 22
Genital Warts (Condylomata Acuminata) - Pipeline by LEO Pharma A/S, H1 2015 23
Genital Warts (Condylomata Acuminata) - Pipeline by MediGene AG, H1 2015 24
Genital Warts (Condylomata Acuminata) - Pipeline by NanoViricides, Inc., H1 2015 25
Genital Warts (Condylomata Acuminata) - Pipeline by Novan, Inc., H1 2015 26
Genital Warts (Condylomata Acuminata) - Pipeline by Tamir Biotechnology, Inc., H1 2015 27
Assessment by Monotherapy Products, H1 2015 28
Number of Products by Stage and Target, H1 2015 30
Number of Products by Stage and Mechanism of Action, H1 2015 32
Number of Products by Stage and Route of Administration, H1 2015 34
Number of Products by Stage and Molecule Type, H1 2015 36
Genital Warts (Condylomata Acuminata) Therapeutics - Recent Pipeline Updates, H1 2015 56
Genital Warts (Condylomata Acuminata) - Dormant Projects, H1 2015 59
Genital Warts (Condylomata Acuminata) - Discontinued Products, H1 2015 60

List of Figures
Number of Products under Development for Genital Warts (Condylomata Acuminata), H1 2015 9
Number of Products under Development for Genital Warts (Condylomata Acuminata) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Products, H1 2015 14
Assessment by Monotherapy Products, H1 2015 28
Number of Products by Top 10 Targets, H1 2015 29
Number of Products by Stage and Top 10 Targets, H1 2015 30
Number of Products by Top 10 Mechanism of Actions, H1 2015 31
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 32
Number of Products by Top 10 Routes of Administration, H1 2015 33
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 34
Number of Products by Top 10 Molecule Types, H1 2015 35
Number of Products by Stage and Top 10 Molecule Types, H1 2015 36

Explore more reports on Diseases & treatment at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment

About RnRMarketResearch.com
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.